Reaction

Subclavian Vein Thrombosis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,128 reports · 51 co-occurring drugs

As of the last recalculation, Subclavian Vein Thrombosis appears in 1,128 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is DROSPIRENONE AND ETHINYL ESTRADIOL (PRR 54.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Drospirenone And Ethinyl Estradiol	117	54.4	54.5
Eplerenone	24	35.3	35.4
Fluticasone Furoate	20	31.0	31.0
Lapatinib	19	23.0	23.0
Ciclesonide	14	19.2	19.2
Pegaspargase	12	18.3	18.3
Leucovorin Calcium	18	17.6	17.7
Heparin Sodium	13	17.6	17.6
Fluorouracil Cream, 0.5%	67	17.2	17.2
Fluorouracil	67	16.9	16.9
Telmisartan	16	16.8	16.8
Polatuzumab Vedotin	8	15.2	15.2
Bleomycin Sulfate	8	14.4	14.4
Progesterone	17	13.9	13.9
Cyclophosphamide Injection, Solution	116	13.4	13.4
Cyclophosphamide	116	13.4	13.4
Cyclophosphamide For Injection	116	13.4	13.4
Paclitaxel (Aibumin-Bound)	56	13.2	13.2
Exemestane	15	13.1	13.1
Panitumumab	11	13.1	13.1
Nebivolol	11	12.9	12.9
Docetaxel Anhydrous	45	12.8	12.8
Docetaxel	45	12.8	12.8
Etonogestrel And Ethinyl Estradiol	15	12.6	12.6
Letrozole Tablets	32	12.6	12.6
Cisplatin	51	12.6	12.6
Paclitaxel	62	12.2	12.2
Vincristine Sulfate	19	12.2	12.2
Doxorubicin	56	12.1	12.2
Doxorubicin Hydrochloride	21	12.1	12.1
Bendamustine Hcl	10	12.0	12.0
Cytarabine	37	11.7	11.7
Filgrastim	23	11.5	11.5
Teduglutide	8	11.0	11.0
Ado-Trastuzumab Emtansine	5	11.0	11.0
Trastuzumab	39	10.8	10.8
Fosaprepitant Dimeglumine	8	10.8	10.8
Cetuximab	17	10.1	10.2
Irinotecan Hydrochloride	7	10.1	10.1
Gemcitabine	21	10.0	10.0
Pertuzumab	13	8.9	8.9
Crizotinib	6	8.8	8.8
Romiplostim	7	8.6	8.6
Gemcitabine Hydrochloride	23	8.1	8.1
Pemetrexed	9	7.8	7.8
Pemetrexed Disodium	15	7.3	7.4
Sacubitril And Valsartan	36	5.9	5.9
Abemaciclib	6	5.6	5.6
Pegfilgrastim	29	5.5	5.5
Evolocumab	35	4.1	4.1
Levonorgestrel	34	3.2	3.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.